{"classes":[{"categories":[{"measurements":[{"comment":"Due to the high number of censored participants, there were not enough events to estimate the median and 95% confidence interval.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Due to the high number of censored participants, there were not enough events to estimate the median and 95% confidence interval.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"313"},{"groupId":"OG001","value":"317"}],"units":"Participants"}],"description":"Time to sustained worsening of worst pain is defined as the time from randomization to the first increase (≥2 points) in the weekly average of the worst pain score, with confirmation in the next consecutive week. It was measured by the Worst Pain Numeric Rating Scale (NRS). NRS is a single-item, participant-administered, 11-point horizontal scale ranging from 0 to 10, with 0 representing \"no pain\" and 10 representing \"pain as bad as you can imagine.\" Participants not known to have sustained worsening will be censored at the last documented assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Imlunestrant 400 milligrams (mg) orally once daily on days 1 to 28 of a 28-day cycle, until disease progression or a criterion for discontinuation were met.","id":"OG000","title":"Arm A: Imlunestrant"},{"description":"Participants received the investigator's choice of endocrine therapy, either exemestane 25 mg administered orally once daily on days 1 to 28 of a 28-day cycle, or Fulvestrant 500 mg intramuscularly on days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond, until disease progression or a criterion for discontinuation was met.","id":"OG001","title":"Arm B: Investigator's Choice of Endocrine Therapy"}],"paramType":"MEDIAN","populationDescription":"All participants who were randomly assigned to either arm A or arm B and had at least one NRS assessment available (including censored). Number of participants censored in \"Arm A=258,\" \"Arm B=267.\"","reportingStatus":"POSTED","timeFrame":"Randomization through follow-up (up to 24 months)","title":"Time to Sustained Worsening of the \"Worst Pain\" as Measured by Worst Pain NRS (Between Arm A and Arm B)","type":"SECONDARY","unitOfMeasure":"Months"}